Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39587
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Williams T. | en |
dc.contributor.author | McLean C.A. | en |
dc.contributor.author | Butler E. | en |
dc.contributor.author | Fok A. | en |
dc.date.accessioned | 2021-05-14T13:30:43Z | en |
dc.date.available | 2021-05-14T13:30:43Z | en |
dc.date.copyright | 2016 | en |
dc.date.created | 20171227 | en |
dc.date.issued | 2017-12-27 | en |
dc.identifier.citation | Multiple Sclerosis Journal. 22 (11) (pp 1495-1498), 2016. Date of Publication: 01 Oct 2016. | en |
dc.identifier.issn | 1352-4585 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/39587 | en |
dc.description.abstract | We report two patients with relapsing remitting multiple sclerosis (RRMS) on interferon (IFN) beta-1a treatment for more than 7 years who developed pulmonary arterial hypertension (PAH). Patient 1 developed severe PAH requiring lung transplantation. Histology showed typical proliferative lesions including plexiform lesions consistent with PAH. Patient 2 ceased IFN beta-1a, and their symptoms stabilised. Both cases highlight IFN beta-1a treatment as a potential risk factor for PAH. PAH needs to be considered as a diagnosis in patients on long-term IFN beta-1a treatment who develop new-onset respiratory symptoms.Copyright © The Author(s), 2015. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | SAGE Publications Ltd (E-mail: info@sagepub.co.uk) | en |
dc.relation.ispartof | Multiple Sclerosis Journal | en |
dc.title | Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients. | en |
dc.type | Article | en |
dc.type.studyortrial | Case series or case report | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1177/1352458515618020 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.source | 619851971 | en |
dc.identifier.institution | (Fok) Department of Ophthalmology & Visual Sciences, Faculty of Medicine, Eye Care Centre (Vancouver General Hospital), Vancouver, BC, Canada (Fok, Butler) Department of Neurosciences, Monash Health, Melbourne, VIC, Australia (Williams) Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, VIC, Australia (McLean) Department of Anatomical Pathology, Alfred Hospital, Melbourne, VIC, Australia | en |
dc.description.address | A. Fok, Department of Ophthalmology & Visual Sciences, Faculty of Medicine, Eye Care Centre (Vancouver General Hospital), 2550 Willow Street, Vancouver, BC V5Z 3N9, Canada. E-mail: anfernee45@hotmail.com | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2017 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Beta-interferon Interferon Multiple sclerosis Pulmonary arterial hypertension | en |
dc.identifier.authoremail | Fok A.; anfernee45@hotmail.com | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Neurology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.